Literature DB >> 1381143

Combination chemotherapy and radiation for palliation of hepatocellular carcinoma.

V Dhir1, V S Swaroop, K M Mohandas, K A Dinshaw, D C Desai, A Nagral, V Sharma, P Jagannath, L J Desouza.   

Abstract

Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy). The response was assessed by liver size on clinical examination. One patient had complete response, and six patients had partial response. The overall response to the treatment was 25.9%. More than a 50% reduction in serum alfa-fetoprotein level was noted in 66.6% patients. Seventy-one percent of patients had palliation of pain following therapy. The median survival of responders was 11 months and of nonresponders, 2 months. Radiation was discontinued in two patients who developed radiation hepatitis. Additional trials with different dosages and schedules are needed to fully evaluate this form of therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381143     DOI: 10.1097/00000421-199208000-00005

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

Review 1.  Role of external beam radiation therapy in management of hepatocellular carcinoma.

Authors:  Hanish Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-07-19

Review 2.  The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Vivek A Saraswat; Anil Arora; Ajay Duseja; Mahesh K Goenka; Deepali Jain; Premashish Kar; Manoj Kumar; Vinay Kumaran; Kunisshery M Mohandas; Dipanjan Panda; Shashi B Paul; Jeyamani Ramachandran; Hariharan Ramesh; Padaki N Rao; Samir R Shah; Hanish Sharma; Ragesh B Thandassery
Journal:  J Clin Exp Hepatol       Date:  2014-05-22

3.  The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care.

Authors:  Hyuk Soo Eun; Min Jung Kim; Hye Jin Kim; Kwang Hun Ko; Hee Seok Moon; Eaum Seok Lee; Seok Hyun Kim; Heon Young Lee; Byung Seok Lee
Journal:  Korean J Hepatol       Date:  2011-09

Review 4.  3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  Li-Qun Zou; Bing-Lan Zhang; Qing Chang; Fu-Ping Zhu; Yan-Yan Li; Yu-Quan Wei; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

5.  Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.

Authors:  Jeng-Nian Yuan; Yee Chao; Wei-Ping Lee; Chung-Pin Li; Rheun-Chuan Lee; Full-Young Chang; Sang-Hue Yen; Shou-Dong Lee; Jacqueline Whang-Peng
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

6.  The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size.

Authors:  Sae Byeol Choi; Kyung Sik Kim; Young Nyun Park; Jin Sub Choi; Woo Jung Lee; Jinsil Seong; Kwang-Hyub Han; Jong Tae Lee
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.